Helix BioPharma Corp., a clinical-stage oncology company, has released its unaudited interim financial statements for the three- and six-month periods ended January 31, 2026, alongside management discussion and analysis and executive certifications. The company reported a net and total comprehensive loss from operations of $694,000 for the three-month period and $1,702,000 for the six-month period, representing decreases from losses of $1,375,000 and $2,711,000 for the comparable periods in 2025. This reduction in net loss was attributed primarily to the conclusion of the LDOS006 clinical trial in metastatic pancreatic adenocarcinoma and scaled-back research activities, though partially offset by increased operating, general, and administrative expenses related to accounting, tax, legal, and consulting fees.
The financial results translate to a loss per common share of $0.01 for the three months and $0.05 for the six months ended January 31, 2026, compared to losses of $0.03 and $0.02 per share for the respective periods in 2025. A critical concern highlighted in the report is the company's cash position, which stood at $31,000 as of January 31, 2026, a sharp decline from $1,996,000 at the end of the comparable quarter in 2025. Helix BioPharma stated that its existing cash reserves are insufficient to meet anticipated cash needs for working capital and capital expenditures over the next twelve months and are also inadequate to complete current research and development activities.
Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix BioPharma, acknowledged the challenging capital markets environment for small-cap biotech firms but emphasized the company's focus on securing necessary financing. "The Management and Board are actively pursuing financing opportunities aimed at securing approximately twelve months of operating runway, which will allow the Company to pursue its near-term objectives, including listing on a U.S. securities exchange," Mehrling stated. He added that while work remains, the company is cautiously optimistic and expects to communicate further on its roadmap soon.
The financial update revealed a significant setback in funding efforts. On December 5, 2025, Helix entered into a subscription agreement with Quantum Global Ventures AG for the purchase of 18,538,889 common shares at $1.80 per share, representing gross proceeds of $33,370,000. Although the agreement was fully executed, Quantum Global Ventures AG declared bankruptcy after the reporting period, and Helix did not receive any of the subscription proceeds, resulting in the financing not closing. Subsequent to the reporting period, the company signed a term sheet with Alumni Capital Limited regarding a potential financing transaction, though specific commercial terms remain confidential.
For stakeholders and investors seeking detailed financial information, the interim filings are accessible on the company's profile at https://www.sedarplus.ca and on its website at https://www.helixbiopharma.com/filings-and-financials/. The company's pipeline includes Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate targeting CEACAM6-expressing tumors, which has completed Phase Ib studies in non-small cell lung cancer. Helix also advances pre-IND candidates LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, an oral gemcitabine prodrug for advanced cancers.
The financial results underscore the precarious position of many clinical-stage biotech companies navigating capital-intensive drug development. For Helix, the reduced losses reflect strategic adjustments in clinical activities, but the depleted cash reserves pose a substantial risk to ongoing operations and pipeline advancement. The pursuit of new financing, including the potential U.S. listing, is critical not only for the company's survival but also for the progression of its oncology therapies aimed at hard-to-treat cancers. The industry implications highlight the volatility of biotech funding, where promising clinical assets can be jeopardized by external financial disruptions, as seen with the Quantum Global Ventures bankruptcy. Investors and patients awaiting novel treatments will closely monitor Helix's ability to secure the necessary capital to translate its research into viable therapeutic options.
